Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

NCT01307618
completedphase_2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
completedphase_1

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

NCT00002952
completedphase_1

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003792

Clinical Trials (4)

Showing 4 of 4 trials
NCT01307618Phase 2

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Terminated
NCT00085189Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed
NCT00002952Phase 1

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Completed
NCT00003792Phase 1

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4